BiotechTube
Home/Pipeline/PEPR-124 (RT-001)

PEPR-124 (RT-001)

Duchenne Muscular Dystrophy

Phase 2-readyLicensed to Revio Therapeutics

Key Facts

Indication
Duchenne Muscular Dystrophy
Phase
Phase 2-ready
Status
Licensed to Revio Therapeutics
Company
Peptris Technologies Private

About Peptris Technologies Private

AI-driven drug discovery company using proprietary generative AI to design novel molecules and repurpose drugs for oncology, inflammation, and rare diseases.

View full company profile

Therapeutic Areas

OncologyInflammationRare Diseases

Other Duchenne Muscular Dystrophy Drugs

DrugCompanyPhase
MyoPAXonMyogenicaPhase 1
DMD Gene TherapyKinea BioPre-clinical
NS-051/NCNP-04NS PharmaPhase 1/2
UCT-MSC + BiomaterialsVitti LabsPhase 2
Myosana Platform for DMDMyosana TherapeuticsPre-clinical
DMD Genetic Screening PanelNanodigmbioCommercial
KHR‑001KAHR MedicalPreclinical
PF-06939926PfizerPhase 3